Compare Tsumura & Co. with Similar Stocks
Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 77.56
2
Low Debt Company with Strong Long Term Fundamental Strength
3
The company has declared Negative results for the last 4 consecutive quarters
4
With ROE of 10.08%, it has a very attractive valuation with a 0.97 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 282,471 Million (Small Cap)
10.00
NA
0.00%
0.22
10.08%
0.93
Revenue and Profits:
Net Sales:
47,439 Million
(Quarterly Results - Mar 2026)
Net Profit:
6,130 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.99%
0%
-2.99%
6 Months
-9.71%
0%
-9.71%
1 Year
10.1%
0%
10.1%
2 Years
-11.8%
0%
-11.8%
3 Years
38.78%
0%
38.78%
4 Years
24.8%
0%
24.8%
5 Years
4.6%
0%
4.6%
Tsumura & Co. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.24%
EBIT Growth (5y)
12.53%
EBIT to Interest (avg)
77.56
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
0.45
Tax Ratio
24.22%
Dividend Payout Ratio
31.84%
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
9.80%
ROE (avg)
8.00%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
0.97
EV to EBIT
9.88
EV to EBITDA
7.41
EV to Capital Employed
0.97
EV to Sales
1.91
PEG Ratio
1.19
Dividend Yield
NA
ROCE (Latest)
9.86%
ROE (Latest)
10.08%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Jun 2020
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
47,439.00
44,320.00
7.04%
Operating Profit (PBDIT) excl Other Income
10,044.00
10,572.00
-4.99%
Interest
433.00
143.00
202.80%
Exceptional Items
-277.00
0.00
Consolidate Net Profit
6,130.00
6,318.00
-2.98%
Operating Profit Margin (Excl OI)
134.00%
174.80%
-4.08%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 7.04% vs 26.56% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -2.98% vs 2,330.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
192,615.00
181,093.00
6.36%
Operating Profit (PBDIT) excl Other Income
48,282.00
51,296.00
-5.88%
Interest
2,152.00
518.00
315.44%
Exceptional Items
-776.00
-32.00
-2,325.00%
Consolidate Net Profit
30,242.00
34,523.00
-12.40%
Operating Profit Margin (Excl OI)
182.90%
221.60%
-3.87%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 6.36% vs 20.05% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -12.40% vs 91.31% in Mar 2025
About Tsumura & Co. 
Tsumura & Co.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






